Holen Sie sich die Stockscreener-App
25.22
0.04%
0.04
Schlusskurs vom Vortag:
$25.26
Offen:
$25.44
24-Stunden-Volumen:
879.86K
Relative Volume:
0.59
Marktkapitalisierung:
$3.12B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-8.1618
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
-3.18%
1M Leistung:
+27.94%
6M Leistung:
+162.40%
1J Leistung:
+47.68%
1-Tages-Spanne:
$24.67
$25.80
1-Wochen-Bereich:
$24.32
$26.40
52-Wochen-Spanne:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
25.23 | 3.13B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.17 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.87 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.00 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
903.20 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.54 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Is Arcus Biosciences Inc. stock cheap by valuation metricsWeekly Market Outlook & Low Risk High Win Rate Stock Picks - Newser
Can Arcus Biosciences Inc. stock ride next bull market cycleShort Setup & Real-Time Market Trend Scan - Newser
Decheng Capital LLC Has $1.30 Million Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
How Arcus Biosciences Inc. stock performs during market turbulenceJuly 2025 Review & Weekly High Potential Alerts - Newser
What is the fair value estimate for Arcus Biosciences Inc. stock in 2025Earnings Overview Report & Safe Entry Momentum Stock Tips - Newser
How Arcus Biosciences Inc. stock behaves in tightening cyclesJuly 2025 Levels & Weekly High Conviction Ideas - Newser
RCUS: Casdatifan shows superior efficacy in RCC, with pivotal trials and strong financial backing - TradingView
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcus Biosciences, Inc. $RCUS Shares Purchased by Geode Capital Management LLC - MarketBeat
How Arcus Biosciences Inc. stock compares with market leadersJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 1,900 Shares - MarketBeat
Arcus Biosciences stock hits 52-week high at 26.32 USD - Investing.com
SG Americas Securities LLC Buys 17,111 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat
How dovish Fed policy supports Arcus Biosciences Inc. stock2025 Pullback Review & Daily Stock Trend Reports - Newser
Pancreatic Cancer Pipeline Drugs Insights Report 2025 | - openPR.com
Arcus Biosciences Executive Sells Shares - TradingView
Discipline and Rules-Based Execution in RCUS Response - news.stocktradersdaily.com
Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
B of A Securities Maintains Arcus Biosciences (RCUS) Neutral Recommendation - Nasdaq
RCUS: B of A Securities Raises Price Target to $26, Maintains Ne - GuruFocus
Arcus Biosciences (NYSE:RCUS) Sets New 12-Month HighShould You Buy? - MarketBeat
Insider Sell Alert: Goeltz II Robert C. Sells 5,000 Shares of Ar - GuruFocus
Arcus Biosciences Delivers Mixed Results But Keeps Analyst Confidence - Finimize
Arcus Biosciences stock hits 52-week high at 22.13 USD By Investing.com - Investing.com Nigeria
Arcus Biosciences stock hits 52-week high at 22.13 USD - Investing.com India
How Arcus Biosciences Inc. stock benefits from digital adoptionRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Is Arcus Biosciences Inc. stock vulnerable to rate hikesWeekly Stock Report & Technical Analysis for Trade Confirmation - newser.com
Is Arcus Biosciences Inc. stock positioned for digital transformationJuly 2025 Sentiment & Fast Exit Strategy with Risk Control - newser.com
Arcus Biosciences (NYSE:RCUS) NYSE Composite Shows Biotech Energy - Kalkine Media
Will Arcus Biosciences Inc. stock benefit from automation2025 Momentum Check & Smart Money Movement Tracker - newser.com
How strong dollar benefits Arcus Biosciences Inc. stockQuarterly Performance Summary & Reliable Volume Spike Trade Alerts - newser.com
Will Arcus Biosciences Inc. stock recover faster than industryWeekly Profit Analysis & Reliable Breakout Stock Forecasts - newser.com
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity - Stock Titan
Can Arcus Biosciences Inc. stock deliver strong Q4 earningsOptions Play & High Accuracy Trade Signal Alerts - newser.com
Is Arcus Biosciences Inc. stock a buy on dips2025 Big Picture & Safe Entry Zone Identification - newser.com
Does Arcus Biosciences Inc. show high probability of rebound2025 Top Gainers & Reliable Volume Spike Trade Alerts - newser.com
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):